Skip to main content
Zhejiang Starry Pharmaceutical Co., Ltd. logo

Zhejiang Starry Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 603520 ISIN · CNE1000026N8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,501 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603520

About Zhejiang Starry Pharmaceutical Co., Ltd.

https://www.starrypharm.com/

Zhejiang Starry Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and chemical intermediates. The company is a prominent global supplier of X-ray contrast agents, focusing on iodinated media such as Iohexol, Iopamidol, Iodixanol, and Iopromide. In addition to diagnostic imaging agents, its product portfolio includes fluoroquinolone antibiotics like Levofloxacin and Ciprofloxacin. The organization maintains large-scale production facilities compliant with international Good Manufacturing Practice (GMP) standards, serving a diverse clientele of pharmaceutical manufacturers worldwide. By integrating advanced chemical synthesis techniques with rigorous quality control, the company provides essential components for diagnostic imaging and anti-infective therapies.

Recent filings

Filing Released Lang Actions
司太立关于选举第六届董事会职工代表董事的公告
Board/Management Information Classification · 98% confidence The document is a notice from Zhejiang Sitaili Pharmaceutical Co., Ltd. announcing the election of an employee representative director to the company’s sixth board of directors. It describes a change in board composition and the election process, fitting the definition of a Board/Management Information announcement. There is no financial data or regulatory form content, and it is clearly an announcement of a board change. Therefore, it should be classified as MANG.
2026-05-22 Chinese
司太立2025年年度股东会法律意见书
Regulatory Filings Classification · 72% confidence The document is a lengthy legal opinion letter provided by an external law firm regarding the legality of Zhejiang Sih Tai Li Pharmaceutical Co., Ltd.’s 2025 Annual General Meeting – its convening, procedures, participant qualifications, and the vote results. It is not the AGM presentation itself (AGM-R), nor a proxy statement (PSI), nor a standalone voting results announcement (DVA), nor any standard financial report. Instead, it is a compliance/legal opinion filing without a more specific category, making it a general regulatory filing. Therefore, it falls under Regulatory Filings (RNS).
2026-05-20 Chinese
司太立2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a formal announcement of the 2025 annual shareholders’ meeting resolutions, detailing each proposal and the vote counts (agree, oppose, abstain) along with voting percentages and confirmations by lawyers. It is not presenting financial statements itself nor soliciting votes, but rather declaring the official voting results of an AGM. Therefore, it fits the Declaration of Voting Results & Voting Rights Announcements category (DVA).
2026-05-20 Chinese
司太立关于获得政府补助的公告
Regulatory Filings Classification · 89% confidence The document is a short official announcement by Zhejiang Sitaili Pharmaceutical Co. regarding the receipt of government subsidies, with details on amounts and accounting treatment. It is not an earnings release, interim/annual report, board change, dividend notice, or financing transaction. It serves as a regulatory disclosure of a corporate event and does not constitute a full financial report. Therefore, it falls under the general Regulatory Filings category.
2026-05-11 Chinese
司太立关于实际控制人增加一致行动人并在一致行动人之间内部转让股份计划及减持股份计划的公告
Regulatory Filings
2026-05-07 Chinese
司太立关于对外投资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Sitaili Pharmaceutical Co., Ltd. regarding an external investment and related party transaction. It details the company's plan to invest 35 million yuan to increase capital in Zhejiang Jianli Chemical Co., Ltd., acquiring a 3.4483% equity stake. The announcement includes information about the related parties, investment details, pricing, agreements, and risk disclosures. It is a formal disclosure of a capital investment transaction involving related parties, including board approvals and independent director opinions. The document does not contain financial statements or comprehensive financial performance data, nor is it a transcript, report, or presentation. It is a regulatory announcement about a capital investment and related party transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-04-08 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.